Hims HIMS Q1 2026 Earnings Call Transcript

Hims & Hers reported Q1 revenue of $608 million, up 4% year over year, with adjusted EBITDA of $44 million and free cash flow of $53 million despite a $92 million GAAP loss tied to $33 million of restructuring and pivot-related charges. Management raised 2026 revenue guidance to $2.8 billion-$3.0 billion and EBITDA guidance to $275 million-$350 million, while citing strong early demand for branded GLP-1s, including over 125,000 Wegovy shipments in six weeks. The company is also expanding internationally and investing heavily in AI, labs, wearables, and peptides, but margin compression is expected near term as the business scales.

Analysis

The market should treat this as a transition-to-scale quarter rather than a clean fundamental beat. The key second-order effect is that HIMS is deliberately swapping near-term margin quality for a larger, more durable customer funnel: branded GLP-1s are pulling in higher-intent users, which should improve cross-sell into labs, testosterone, and eventually peptides. That mix shift is strategically bullish because it expands lifetime value, but it also raises the probability that headline EBITDA and gross margin stay noisy for the next several quarters even if cash generation holds up.

The most important near-term tell is not the absolute subscriber count; it is the engagement density. If the company can sustain provider interactions and app adoption at this level, the funnel becomes less like a one-off prescription business and more like a recurring care graph, which is exactly what supports lower CAC over time. The risk is that this is still early-cycle behavior: consumer enthusiasm around a new branded obesity channel can fade quickly, and the company is increasingly exposed to refill cadence, payer access, and partner economics rather than purely self-funded demand.

International is the underappreciated swing factor. The ZAVA/LIVWELL base gives HIMS a template for replicating a U.S. playbook abroad, but the near-term earnings contribution will likely be diluted by integration costs and lower margin profiles in newer geographies. The contrarian read is that the stock may be underestimating operating leverage in 2H26 if cohort stacking works as planned, but overestimating how quickly gross margin can normalize; this is the classic setup where revenue estimates keep rising while consensus EPS stays too high.

The hidden catalyst is peptide/regulatory optionality. If FDA clarity lands in July and HIMS can credibly claim a compliant, vertically integrated pathway, the market may start to price it as a multi-category healthcare platform rather than a single GLP-1 story. That re-rating would likely be driven by multiple expansion before the revenue dollars show up, so the trade is about owning optionality ahead of productization rather than waiting for proof in reported revenue.

Key Decisions for Investors

• Long HIMS into the next 4-8 weeks on any post-call weakness; use a starter position and add if the stock de-risks the GAAP noise but holds guide — asymmetric setup if 2H26 cohort stacking drives sequential EBITDA acceleration.
• Buy HIMS Jan-2027 call spreads financed partially by selling nearer-dated upside; thesis is multiple expansion on platform/AI/peptides optionality with limited downside versus outright equity exposure.
• Pair trade: long HIMS / short a basket of lower-growth digital health names with weaker consumer retention economics; HIMS has the stronger self-funded growth profile and more identifiable operating leverage over the next 6-12 months.
• If holding NVO, hedge with a modest short HIMS call position rather than outright equity — HIMS is becoming a distribution partner, but the real risk is channel conflict and pricing pressure if branded GLP-1 economics tighten.
• Tactically avoid chasing after any 1-2 day gap-up; the better entry is after the market digests that 2026 gross margin compression is likely to persist before improving in 2027.